U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H20FN2O4S.Na
Molecular Weight 438.4496
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RAMATROBAN SODIUM

SMILES

c1ccc2c(c1)c3C[C@@]([H])(CCc3n2CCC(=O)[O-])NS(=O)(=O)c4ccc(cc4)F.[Na+]

InChI

InChIKey=JRBVAOJTPBHRQQ-XFULWGLBSA-M
InChI=1S/C21H21FN2O4S.Na/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26;/h1-6,8-9,15,23H,7,10-13H2,(H,25,26);/q;+1/p-1/t15-;/m1./s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H20FN2O4S
Molecular Weight 415.4598
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Ramatroban is a dual antagonist of thromboxane A2 receptor and PGD2 receptor. The drug was developed by Bayer and tested for the treatment of asthma and allergic rhinitis. In Japan ramatroban reached final approval and is being marketed under the name Baynas. In vitro studies have shown that the drug effectively inhibits smooth muscle cells contraction.

CNS Activity

Curator's Comment:: Ramatroban and its labeled metabolites did hardly penetrate the blood-brain barrier.

Originator

Curator's Comment:: # Bayer

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BAYNAS

Approved Use

Treatment of Allergic rhinitis.

Launch Date

9.5264637E11
PubMed

PubMed

TitleDatePubMed
Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats.
2003 Nov
Participation of chemical mediators in the development of experimental allergic conjunctivitis in rats.
2004 Nov
Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2.
2005 Mar
CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses.
2005 Nov 7
Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2.
2005 Sep 16
Involvement of cyclooxygenase-2 in allergic nasal inflammation in rats.
2006 Nov
Patents

Patents

Sample Use Guides

75 mg is administered orally devided in two doses, after breakfast and after dinner (or before going to bed).
Route of Administration: Oral
In Vitro Use Guide
Human airway smooth muscle preparations and lung strips were treated wuth 10(-6), 10(-7) and 10(-8) M of remetroban to inhibit U46619-induced contractions.
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:12:51 UTC 2021
Edited
by admin
on Sat Jun 26 10:12:51 UTC 2021
Record UNII
5J3I129AXS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RAMATROBAN SODIUM
Common Name English
9H-CARBAZOLE-9-PROPANOIC ACID, 3-(((4-FLUOROPHENYL)SULFONYL)AMINO)-1,2,3,4-TETRAHYDRO-, SODIUM SALT (1:1), (3R)-
Systematic Name English
RAMATROBAN SODIUM SALT
Common Name English
Code System Code Type Description
CAS
1040405-44-4
Created by admin on Sat Jun 26 10:12:51 UTC 2021 , Edited by admin on Sat Jun 26 10:12:51 UTC 2021
PRIMARY
PUBCHEM
67027609
Created by admin on Sat Jun 26 10:12:51 UTC 2021 , Edited by admin on Sat Jun 26 10:12:51 UTC 2021
PRIMARY
FDA UNII
5J3I129AXS
Created by admin on Sat Jun 26 10:12:51 UTC 2021 , Edited by admin on Sat Jun 26 10:12:51 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY